CD8A and neoplasm: The immune response against the tumor could differ depending on sex, so that tumor-infiltrating CD8+ cytotoxic lymphocytes and FoxP3+ regulatory T lymphocytes prior to RCT in the biopsy and about 55 days after RCT in the surgical specimen were compared between sexes.